Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56


Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis.

Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, Lutterotti A, Müller A, Stephan KE.

J Neurol Neurosurg Psychiatry. 2019 Jan 25. pii: jnnp-2018-320050. doi: 10.1136/jnnp-2018-320050. [Epub ahead of print]


GDP-l-fucose synthase is a CD4+ T cell-specific autoantigen in DRB3*02:02 patients with multiple sclerosis.

Planas R, Santos R, Tomas-Ojer P, Cruciani C, Lutterotti A, Faigle W, Schaeren-Wiemers N, Espejo C, Eixarch H, Pinilla C, Martin R, Sospedra M.

Sci Transl Med. 2018 Oct 10;10(462). pii: eaat4301. doi: 10.1126/scitranslmed.aat4301.


Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R.

Cell. 2018 Sep 20;175(1):85-100.e23. doi: 10.1016/j.cell.2018.08.011. Epub 2018 Aug 30.


Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.

Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, Reindl M, Weller M, Martin R, Lutterotti A, Schippling S.

J Neuroophthalmol. 2019 Mar;39(1):3-7. doi: 10.1097/WNO.0000000000000669.


Transient impairment of olfactory threshold in acute multiple sclerosis relapse.

Bsteh G, Hegen H, Ladstätter F, Berek K, Amprosi M, Wurth S, Auer M, Di Pauli F, Deisenhammer F, Lutterotti A, Berger T.

Mult Scler Relat Disord. 2018 Jul;23:74-77. doi: 10.1016/j.msard.2018.05.006. Epub 2018 May 26.


Challenges and needs in experimental therapies for multiple sclerosis.

Lutterotti A.

Curr Opin Neurol. 2018 Jun;31(3):263-267. doi: 10.1097/WCO.0000000000000560. Review.


Change of olfactory function as a marker of inflammatory activity and disability progression in MS.

Bsteh G, Hegen H, Ladstätter F, Berek K, Amprosi M, Wurth S, Auer M, Di Pauli F, Deisenhammer F, Reindl M, Berger T, Lutterotti A.

Mult Scler. 2019 Feb;25(2):267-274. doi: 10.1177/1352458517745724. Epub 2017 Nov 29.


Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.

Peschl P, Schanda K, Zeka B, Given K, Böhm D, Ruprecht K, Saiz A, Lutterotti A, Rostásy K, Höftberger R, Berger T, Macklin W, Lassmann H, Bradl M, Bennett JL, Reindl M.

J Neuroinflammation. 2017 Oct 25;14(1):208. doi: 10.1186/s12974-017-0984-5.


CD4+ T-Cell Reactivity to Orexin/Hypocretin in Patients With Narcolepsy Type 1.

Ramberger M, Högl B, Stefani A, Mitterling T, Reindl M, Lutterotti A.

Sleep. 2017 Mar 1;40(3). doi: 10.1093/sleep/zsw070.


Is it Time for Immunotherapy Trials in Narcolepsy?

Lutterotti A.

J Clin Sleep Med. 2017 Mar 15;13(3):363-364. doi: 10.5664/jcsm.6478. No abstract available.


Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.


Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.


Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection.

Misselwitz B, Epprecht J, Mertens J, Biedermann L, Scharl M, Haralambieva E, Lutterotti A, Weber KP, Müllhaupt B, Chaloupka K.

Case Rep Gastroenterol. 2016 May 19;10(1):108-14. doi: 10.1159/000444011. eCollection 2016 Jan-Apr.


Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.

Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, Deisenhammer F, Reindl M, Berger T.

PLoS One. 2016 Jul 8;11(7):e0158978. doi: 10.1371/journal.pone.0158978. eCollection 2016.


Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.

Maurer MA, Tuller F, Gredler V, Berger T, Lutterotti A, Lünemann JD, Reindl M.

J Neuroimmunol. 2016 Jan 15;290:49-53. doi: 10.1016/j.jneuroim.2015.11.006. Epub 2015 Nov 19.


Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.

Ehling R, Di Pauli F, Lackner P, Rainer C, Kraus V, Hegen H, Lutterotti A, Kuenz B, De Zordo T, Schocke M, Glatzl S, Löscher WN, Deisenhammer F, Reindl M, Berger T.

J Neuroimmunol. 2015 Oct 15;287:98-105. doi: 10.1016/j.jneuroim.2015.08.004. Epub 2015 Aug 10.


NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases.

Ramberger M, Bsteh G, Schanda K, Höftberger R, Rostásy K, Baumann M, Aboulenein-Djamshidian F, Lutterotti A, Deisenhammer F, Berger T, Reindl M.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 13;2(5):e141. doi: 10.1212/NXI.0000000000000141. eCollection 2015 Oct.


Non-convulsive status epilepticus with negative phenomena--a SMART syndrome variant.

Hametner E, Unterberger I, Lutterotti A, Beer R, Prieschl M, Grams AE, Donnemiller E, Stockhammer G.

Seizure. 2015 Feb;25:49-51. doi: 10.1016/j.seizure.2014.12.007. Epub 2014 Dec 23. No abstract available.


Damping of monocular pendular nystagmus with vibration in a patient with multiple sclerosis.

Ehling R, Lutterotti A, Brenneis C, Zee DS, Beh SC, Kheradmand A.

Neurology. 2014 Nov 11;83(20):1879. doi: 10.1212/WNL.0000000000000995. No abstract available.


Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells.

Peschl P, Reindl M, Schanda K, Sospedra M, Martin R, Lutterotti A.

Mult Scler. 2015 Apr;21(5):651-5. doi: 10.1177/1352458514549405. Epub 2014 Sep 8.


Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people.

Aboul-Enein F, Seifert-Held T, Mader S, Kuenz B, Lutterotti A, Rauschka H, Rommer P, Leutmezer F, Vass K, Flamm-Horak A, Stepansky R, Lang W, Fertl E, Schlager T, Heller T, Eggers C, Safoschnik G, Fuchs S, Kraus J, Assar H, Guggenberger S, Reisz M, Schnabl P, Komposch M, Simschitz P, Skrobal A, Moser A, Jeschow M, Stadlbauer D, Freimüller M, Guger M, Schmidegg S, Franta C, Weiser V, Koppi S, Niederkorn-Duft M, Raber B, Schmeissner I, Jecel J, Tinchon A, Storch MK, Reindl M, Berger T, Kristoferitsch W.

PLoS One. 2013 Nov 5;8(11):e79649. doi: 10.1371/journal.pone.0079649. eCollection 2013.


Antigen-specific tolerization approaches in multiple sclerosis.

Lutterotti A, Martin R.

Expert Opin Investig Drugs. 2014 Jan;23(1):9-20. doi: 10.1517/13543784.2014.844788. Epub 2013 Oct 23. Review.


Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.

Lutterotti A, Yousef S, Sputtek A, Stürner KH, Stellmann JP, Breiden P, Reinhardt S, Schulze C, Bester M, Heesen C, Schippling S, Miller SD, Sospedra M, Martin R.

Sci Transl Med. 2013 Jun 5;5(188):188ra75. doi: 10.1126/scitranslmed.3006168.


Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.

Gredler V, Mader S, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer F, Berger T, Reindl M, Lutterotti A.

J Neurol Sci. 2013 May 15;328(1-2):77-82. doi: 10.1016/j.jns.2013.02.024. Epub 2013 Mar 21.


No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients.

Lutterotti A, Jelcić I, Schulze C, Schippling S, Breiden P, Mazzanti B, Reinhardt S, DiGioia M, Repice A, Massacesi L, Sputtek A, Salinas-Riester G, Kroeger N, Sospedra M, Saccardi R, Zander A, Martin R.

Mult Scler. 2012 Aug;18(8):1188-92. doi: 10.1177/1352458511434067. Epub 2012 Jan 17.


Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.

Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M.

J Neuroinflammation. 2011 Dec 28;8:184. doi: 10.1186/1742-2094-8-184.


Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis.

Ehling R, Pauli FD, Lackner P, Kuenz B, Santner W, Lutterotti A, Gneiss C, Hegen H, Schocke M, Deisenhammer F, Berger T, Reindl M.

Fluids Barriers CNS. 2011 Oct 26;8(1):25. doi: 10.1186/2045-8118-8-25.


Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

Hegen H, Schleiser M, Gneiss C, Di Pauli F, Ehling R, Kuenz B, Lutterotti A, Berger T, Deisenhammer F.

Mult Scler. 2012 May;18(5):610-5. doi: 10.1177/1352458511426738. Epub 2011 Oct 19.


Olfactory threshold is impaired in early, active multiple sclerosis.

Lutterotti A, Vedovello M, Reindl M, Ehling R, DiPauli F, Kuenz B, Gneiss C, Deisenhammer F, Berger T.

Mult Scler. 2011 Aug;17(8):964-9. doi: 10.1177/1352458511399798. Epub 2011 Mar 3.


Natalizumab treatment reduces endothelial activity in MS patients.

Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F.

J Neuroimmunol. 2010 Oct 8;227(1-2):190-4. doi: 10.1016/j.jneuroim.2010.07.012. Epub 2010 Aug 23.


Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica.

Mader S, Lutterotti A, Di Pauli F, Kuenz B, Schanda K, Aboul-Enein F, Khalil M, Storch MK, Jarius S, Kristoferitsch W, Berger T, Reindl M.

PLoS One. 2010 May 5;5(5):e10455. doi: 10.1371/journal.pone.0010455.


Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.

Gneiss C, Koudouovoh-Tripp PM, Ropele S, Gotwald T, Ehling R, Lutterotti A, Aichner F, Ladurner G, Eggers C, Schautzer F, Künz B, Millonig A, Aspeck E, Reindl M, Berger T, Fazekas F, Deisenhammer F.

Mult Scler. 2009 Dec;15(12):1481-8. doi: 10.1177/1352458509347153. Epub 2009 Nov 13.


Features of intrathecal immunoglobulins in patients with multiple sclerosis.

Di Pauli F, Gredler V, Kuenz B, Lutterotti A, Ehling R, Gneiss C, Schocke M, Deisenhammer F, Reindl M, Berger T.

J Neurol Sci. 2010 Jan 15;288(1-2):147-50. doi: 10.1016/j.jns.2009.09.016. Epub 2009 Oct 13.


EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.

Lünemann JD, Jelcić I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Münz C.

J Exp Med. 2008 Aug 4;205(8):1763-73. doi: 10.1084/jem.20072397. Epub 2008 Jul 28.


Smoking is a risk factor for early conversion to clinically definite multiple sclerosis.

Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, O'Reilly E, Munger K, Deisenhammer F, Ascherio A, Berger T.

Mult Scler. 2008 Sep;14(8):1026-30. doi: 10.1177/1352458508093679. Epub 2008 Jul 16.


Antigen-specific therapies in MS - Current concepts and novel approaches.

Lutterotti A, Sospedra M, Martin R.

J Neurol Sci. 2008 Nov 15;274(1-2):18-22. doi: 10.1016/j.jns.2008.05.021. Epub 2008 Jul 3. Review.


Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis.

Kuenz B, Lutterotti A, Ehling R, Gneiss C, Haemmerle M, Rainer C, Deisenhammer F, Schocke M, Berger T, Reindl M.

PLoS One. 2008 Jul 2;3(7):e2559. doi: 10.1371/journal.pone.0002559.


Getting specific: monoclonal antibodies in multiple sclerosis.

Lutterotti A, Martin R.

Lancet Neurol. 2008 Jun;7(6):538-47. doi: 10.1016/S1474-4422(08)70110-8. Review.


Biological markers for multiple sclerosis.

Lutterotti A, Berger T, Reindl M.

Curr Med Chem. 2007;14(18):1956-65. Review.


Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.

Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, Lutterotti A, Khalil M, Kuenz B, Mayringer I, Reindl M, Berger T, Deisenhammer F.

Mult Scler. 2006 Dec;12(6):731-7.


Increased serum levels of soluble CD14 indicate stable multiple sclerosis.

Lutterotti A, Kuenz B, Gredler V, Khalil M, Ehling R, Gneiss C, Egg R, Deisenhammer F, Berger T, Reindl M.

J Neuroimmunol. 2006 Dec;181(1-2):145-9. Epub 2006 Oct 13.


Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.

Gneiss C, Tripp P, Ehling R, Khalil M, Lutterotti A, Egg R, Mayringer I, Künz B, Berger T, Reindl M, Deisenhammer F.

J Neuroimmunol. 2006 May;174(1-2):174-9. Epub 2006 Mar 23.


Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments.

Khalil M, Reindl M, Lutterotti A, Kuenz B, Ehling R, Gneiss C, Lackner P, Deisenhammer F, Berger T.

J Neuroimmunol. 2006 May;174(1-2):147-56. Epub 2006 Mar 6.


Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis.

Kuenz B, Lutterotti A, Khalil M, Ehling R, Gneiss C, Deisenhammer F, Reindl M, Berger T.

J Neuroimmunol. 2005 Oct;167(1-2):143-9.


Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis.

Ehling R, Lutterotti A, Wanschitz J, Khalil M, Gneiss C, Deisenhammer F, Reindl M, Berger T.

Mult Scler. 2004 Dec;10(6):601-6.


Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

Gneiss C, Reindl M, Lutterotti A, Ehling R, Egg R, Khalil M, Berger T, Deisenhammer F.

Mult Scler. 2004 Oct;10(5):507-10.


Epitope specificity of neutralizing antibodies against IFN-beta.

Gneiss C, Reindl M, Berger T, Lutterotti A, Ehling R, Egg R, Deisenhammer F.

J Interferon Cytokine Res. 2004 May;24(5):283-90.


Genetic variants in the tumor necrosis factor receptor II gene in patients with multiple sclerosis.

Ehling R, Gassner Ch, Lutterotti A, Strasser-Fuchs S, Kollegger H, Kristoferitsch W, Reindl M, Berger T.

Tissue Antigens. 2004 Jan;63(1):28-33.


Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders.

Reindl M, Khantane S, Ehling R, Schanda K, Lutterotti A, Brinkhoff C, Oertle T, Schwab ME, Deisenhammer F, Berger T, Bandtlow CE.

J Neuroimmunol. 2003 Dec;145(1-2):139-47.


A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions.

Lassmann H, Reindl M, Rauschka H, Berger J, Aboul-Enein F, Berger T, Zurbriggen A, Lutterotti A, Brück W, Weber JR, Ullrich R, Schmidbauer M, Jellinger K, Vandevelde M.

Brain. 2003 Jun;126(Pt 6):1347-57.


Supplemental Content

Loading ...
Support Center